Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 15/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MC5R | P33032 | 1/20 | 0.49 |
| ▸ | MC3R | P41968 | 1/20 | 0.49 |
| ▸ | MC1R | Q01726 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677238 | 0.90 | MC4R (0.58) | MC4RKMT2AMEN1ALDH1A1MC5R | |
| SCHEMBL4520460 | 0.90 | MC4R (0.60) | MC4RKMT2AMEN1ALDH1A1MC5R | |
| SCHEMBL4523143 | 0.86 | MC4R (0.63) | MC4RKMT2AMEN1ALDH1A1MC5R | |
| SCHEMBL4519772 | 0.85 | MC4R (0.58) | MC4RKMT2AMEN1ALDH1A1MC5R | |
| SCHEMBL4521475 | 0.85 | MC4R (0.56) | MC4RKMT2AMEN1ALDH1A1MC5R | |
| SCHEMBL4521567 | 0.81 | MC4R (0.80) | MC4RKMT2AMEN1ALDH1A1 | |
| SCHEMBL4523145 | 0.80 | MC4R (0.58) | MC4RMC5RMC3RMC1R | |
| SCHEMBL14355697 | 0.79 | MC4R (0.86) | MC4RMC5RMC3RMC1R | |
| SCHEMBL4514833 | 0.79 | MC4R (0.86) | MC4RMC5RMC3RMC1R | |
| SCHEMBL4517301 | 0.78 | MC4R (0.61) | MC4RKMT2AMEN1ALDH1A1MC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MC4R 2/4885KMT2A 1330/4885MEN1 1339/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MC4R 2/4885KMT2A 1330/4885MEN1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.